300791.SHE Sirio Pharma
- Market cap
- CNY 5.27B
- P/E
- 47.5x
- P/B
- 1.66x
- ROE
- 9.9%
- Dividend yield
- 3.47%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300791.SHE undervalued?
Graham number300791.SHE trades 87.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sirio Pharma fundamental analysis
No fundamental analysis for Sirio Pharma yet.
Sirio Pharma stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sirio Pharma
Sirio Pharma Co., Ltd. operates as a contract manufacturer for dietary supplement industry China, the United States, Europe, and internationally. The company develops and manufactures a range of softgel dietary supplements; vegetarian softgel; nutritious gummies; liquids; probiotic balls; tablet and powder products; capsules; and functional beverages for beauty and wellness, gut health, bone and joint health, immune and fertility support, cardiovascular and metabolic health,…
Full company profileSirio Pharma financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sirio Pharma annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 786M | 1.33B | 1.60B | 1.58B | 2.07B | 2.37B | 2.51B | 3.58B | 4.21B | 4.26B | 4.09B |
| Gross Profit | 251M | 434M | 541M | 510M | 662M | 765M | 770M | 1.08B | 1.32B | 1.30B | 1.40B |
| Operating Income | 933M | 126M | 228M | 152M | 316M | 290M | 265M | 282M | 327M | 329M | 476M |
| EBITDA | 80.8M | 198M | 283M | 225M | 354M | 379M | 367M | 597M | 612M | 355M | 426M |
| Net Income | 704M | 104M | 203M | 143M | 257M | 232M | 212M | 281M | 325M | 137M | 306M |
| EPS | 5.21 | 0.77 | 1.51 | 0.79 | 1.43 | 1.29 | 1.17 | 1.20 | 1.39 | 0.44 | 0.99 |
| Balance Sheet | |||||||||||
| Total Assets | 1.47B | 1.29B | 1.54B | 2.36B | 2.65B | 3.82B | 4.19B | 5.20B | 5.49B | 5.59B | 6.06B |
| Total Liabilities | 1.01B | 708M | 760M | 414M | 467M | 1.28B | 1.48B | 2.63B | 2.84B | 2.63B | 2.99B |
| Shareholders' Equity | 462M | 580M | 784M | 1.95B | 2.18B | 2.54B | 2.70B | 2.39B | 2.51B | 2.94B | 3.09B |
| Cash & Short-term Investments | 273M | 115M | 72.4M | 395M | 690M | 1.25B | 1.58B | 735M | 751M | 595M | 875M |
| Total Debt | 391M | 373M | 431M | 99.8M | 34.7M | 874M | 937M | 1.31B | 1.54B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -98.3M | 49.4M | 183M | 232M | 320M | 341M | 445M | 386M | 567M | 570M | - |
| Capital Expenditure | 72.7M | 160M | 239M | 167M | 223M | 525M | 294M | 452M | 412M | 441M | 372M |
| Free Cash Flow | -171M | -110M | -55.9M | 64.7M | 96.4M | -183M | 151M | -65.6M | 155M | 129M | 39.8M |
| Ratios | |||||||||||
| ROE | 152.3% | 18.0% | 25.9% | 7.3% | 11.8% | 9.1% | 7.9% | 11.8% | 13.0% | 4.6% | 9.9% |
| ROA | 47.7% | 8.1% | 13.2% | 6.0% | 9.7% | 6.1% | 5.1% | 5.4% | 5.9% | 2.4% | 5.1% |
| Net Profit Margin | 89.5% | 7.8% | 12.7% | 9.0% | 12.5% | 9.8% | 8.5% | 7.8% | 7.7% | 3.2% | 7.5% |
| Debt to Equity | 0.85x | 0.64x | 0.55x | 0.05x | 0.02x | 0.34x | 0.35x | 0.55x | 0.61x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sirio Pharma dividends
- Dividend yield
- 3.47%
- Forward dividend
- 0.13 CNY
- Payout ratio
- 134.1%
- Ex-dividend date
- Jun 5, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 183M | 0.59 | 134.1% |
| 2024 | CNY 220M | 0.94 | 67.6% |
| 2023 | CNY 83.8M | 0.36 | 29.8% |
| 2022 | CNY 76.1M | 0.42 | 35.8% |
| 2021 | CNY 72.5M | 0.40 | 31.3% |
| 2020 | CNY 25.9M | 0.14 | 10.0% |
| 2019 | CNY 14.3M | 0.08 | 10.0% |
| 2018 | CNY 44.3M | 0.33 | 21.8% |
| 2017 | CNY 225M | 1.67 | 216.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on May 27, 2025.
Who owns Sirio Pharma
- Insiders 66.25%
- Institutions 8.59%
- Public & others 25.17%
- Shares outstanding 308M
- Free float 108M
Sirio Pharma company profile
- Company name
- Sirio Pharma
- Ticker
- 300791.SHE
- ISIN
- CNE100003NB0
- Exchange
- Shenzhen Stock Exchange
- Sector
- Consumer Defensive
- Industry
- Food Products
- Employees
- 2,776
- Fiscal year end
- December
- Address
- No. 83, Taishan Road, Shantou, China, 515000
- Phone
- 86 754 8892 4286
- Website
- siriopharma.com
About Sirio Pharma
Sirio Pharma Co., Ltd. operates as a contract manufacturer for dietary supplement industry China, the United States, Europe, and internationally. The company develops and manufactures a range of softgel dietary supplements; vegetarian softgel; nutritious gummies; liquids; probiotic balls; tablet and powder products; capsules; and functional beverages for beauty and wellness, gut health, bone and joint health, immune and fertility support, cardiovascular and metabolic health, and healthy ageing. It also offers formulation; technical, and research and development support; and primary and final packaging services. Sirio Pharma Co., Ltd. was founded in 1993 and is headquartered in Shantou, China.
Sirio Pharma management
5- Mr. Peiqing LiGM & Chairman of the Board · born 1965
- Ms. Liqun ZhengDeputy GM & CFO · born 1971
- Ms. Qiong ChenDeputy GM & Director · born 1966
- Mr. Ruoyang LiuDeputy GM & Board Secretary · born 1989
- Ya SongAccounting Supervisor